AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) dropped 0.3% during trading on Thursday. The stock traded as low as $2.75 and last traded at $2.89. Approximately 102,557 shares changed hands during mid-day trading, an increase of 554% from the average daily volume of 15,685 shares. The stock had previously closed at $2.90.
AlloVir Price Performance
The stock’s fifty day moving average price is $3.66 and its 200-day moving average price is $4.70. The firm has a market cap of $14.37 million, a PE ratio of -0.14 and a beta of 0.63.
AlloVir Company Profile
AlloVir, Inc was a biotechnology company focused on developing allogeneic, virus-specific T-cell therapies for people whose immune systems are compromised, including recipients of organ or stem-cell transplants. Its research sought to address serious viral infections that can occur when patients cannot mount an effective immune response.
The company’s leading investigational product was posoleucel, also known as ALVR105, an “off-the-shelf” multivirus-specific T-cell therapy designed to target several viruses, including cytomegalovirus, Epstein-Barr virus, adenovirus, BK virus and human herpesvirus 6.
Featured Stories
- Five stocks we like better than AlloVir
- Plexus Is Booming—But Can the Growth Story Last?
- Conagra’s Turnaround Is Starting to Show Up in the Numbers
- MarketBeat Week in Review – 09/28 – 10/02
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
